Navigation Links
Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
Date:4/16/2008

SNS-032 Demonstrates Activity in Multiple Myeloma and Mantle Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data from studies conducted in collaboration with the Multiple Myeloma Research Consortium (MMRC) and with the University of Texas MD Anderson Cancer Center were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, CA. SNS-032, a potent and selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, is currently in a Phase 1 clinical trial in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma.

"Our collaborations with leading oncology thought leaders, such as Dr. Trudel and the MMRC Validation Team and Dr. Plunkett of MD Anderson Cancer Center, provide us with important new insights into SNS-032's activity in hematologic cancers," said Daniel C. Adelman, M.D., Senior Vice President, Development and Chief Medical Officer of Sunesis. "Results presented today from studies in primary and human cell lines demonstrate SNS-032's potential both alone and in combination with other agents in multiple myeloma and other B cell malignancies and further support our ongoing Phase 1 clinical trial."

An oral presentation by Suzanne Trudel, MSc, M.D., Assistant Professor, Princess Margaret Hospital, University Health Network in Toronto, Canada, focused on results from studies by the MMRC Validation Team, in collaboration with Sunesis scientists, of SNS-032 in human myeloma cell lines and primary multiple myeloma cells. SNS-032 demonstrated broad, mechanism-based activity in the human my
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
2. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
3. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
5. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
6. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
7. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
8. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
11. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the ... Product & by End User - Global Forecast to 2019" ... allergy diagnostics market is valued at $1,228.58 million in 2014 ... to reach $2,230.72 million by 2019. Allergy diagnostics is used ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... headquartered in Greenville, SC, announced today that its Glucommander™ 2.0 ... use, ages 2 - 17. Glytec,s Glucommander was the first ... intravenous use; it is the only company to ... the only company cleared to offer this technology to hospitals ...
... LAKES, N.J. and OLATHE, Kan., May 21, 2012  BD ... a leading global medical technology company, and Heart to ... teaming up for their second joint volunteer initiative to ... employees from around the world will build upon the ...
Cached Medicine Technology:Glytec Adds Pediatric Insulin Dosing to its IV and SubQ FDA Clearances 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
(Date:1/22/2015)... Lynchburg, Va. (PRWEB) January 22, 2015 Liberty ... Health Counseling (M.A.) program from the Council for ... The program, part of Liberty’s Center for Counseling & ... Hawkins, founding dean of the university’s new School of Behavioral ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2
... (FRG) is pleased to announce the hiring of Dr. ... Operations. Katyal will be joining them from,West Penn Hospital, ... and Past President of the Pittsburgh Radiology Society. , ... widely regarded as the preeminent cardiovascular imager in,Western Pennsylvania. ...
... VEGAS, Nov. 25 Stop and think. That is what,Las ... Golden,Rainbow are asking Las Vegas to do this World AIDS ... marking the day with a,fundraising dinner to re-launch a new ... , For the past ...
... 25 H. Paul Dorman, Chairman and Chief Executive ... that Travis E. Baugh has joined HEALTHPOINT(R), Ltd., a ... , , ... a global operations and financial executive in a variety ...
... JNJ ) is commencing today, through a new wholly-owned ... all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. (Nasdaq: ... 24, 2008, its intent to acquire Omrix. , ... offer, stockholders of Omrix will receive $25.00 in cash for each ...
... receive breast-conserving therapy and radiation do not need ... despite current American Society of Clinical Oncology (ASCO) ... recommend follow-up mammograms at between six and 12 ... study in the International Journal of Radiation ...
... Secretary of Labor Elaine L. Chao today announced the appointment ... Occupational Safety and Health (NACOSH). The committee, established under ... Secretaries of labor and health and human services on occupational ... "We appreciate the advisory committee members, willingness to ...
Cached Medicine News:Health News:Foundation Radiology Group Adds World Class Cardiovascular Imaging Expert, Dr. Sanj Katyal, to Staff 2Health News:Las Vegas Charities Mark World AIDS Day by Asking Residents to 'THINK' 2Health News:Travis E. Baugh Named President, COO of HEALTHPOINT, Ltd. 2Health News:Johnson & Johnson Begins Tender Offer to Acquire Omrix 2Health News:Johnson & Johnson Begins Tender Offer to Acquire Omrix 3Health News:Mammogram most effective 12 months after radiation treatment 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 2Health News:U.S. Labor Secretary Elaine L. Chao announces new membership of OSHA advisory committee 3
... Microdiathermy System features an advanced design, solid ... as well as many years of clinical ... optimum choice for the placement of discrete ... burns produce the maximum effect at the ...
The EL401 Manual Plate/Strip Washer accommodates all 96-well microplates and microwell strips. The unique alignment mechanism allows quick and accurate positioning of the 8- or 12-channel manifold ab...
... Philips SureSigns C1 compact, portable ... vital signs as well as versatile ... The C1, ideal for transport and ... user interface and provides the flexibility ...
Compact networked patient monitors for flexible care....
Medicine Products: